Wrong commercial strategy?

It's nearly been 18 months since our successful phase 2 smoking cessation results were published. Quite clearly big pharma are not interested in smoking cessation drugs ( probably because they get sued).
So, we ditch that idea and therefor there is no short path to market. Big pharma also don't seem interested in a widely available generic drug that is contraindicated in asthma and copd. After all, and on top of the contraindication, if they try to put a premium price on the drug, a doctor can simply prescribe the drug off label and in nearly all instances get away with it. The drug proprietary dose protection we have must be non obvious for those skilled in the art, and even that might not be enough. On top of that, maybe the inhaled route becomes too expensive, it could then be compromised by the cheap generic oral drug?
So where to now? A powerful route to market exclusivity would be a combination with a second drug?
If there is still anybody out there ... thoughts?